Wood Morgan Colby
Known title: DirectorCIK: 0001881573
Wood Morgan Colby's purchase track record
Wood Morgan Colby has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/11/2022 | PRCT | $23K | +64.0% | +103.2% | -3.3% |
| 9/17/2021 | PRCT | $170K | -36.4% | -17.5% | +0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PRCT | ▼ Sell | Open Market | 25,000 | $805K | 11/13/2023 | View on chart |
| PRCT | ▲ Buy | Grant | 2,711 | $0 | 6/15/2023 | View on chart |
| PRCT | ▼ Sell | Open Market | 12,203 | $439K | 3/3/2023 | View on chart |
| PRCT | ▼ Sell | Open Market | 2,797 | $104K | 3/3/2023 | View on chart |
| PRCT | ▲ Buy | Grant | 2,001 | $75K | 6/7/2022 | View on chart |
| PRCT | ▲ Buy | Open Market | 940 | $23K | 3/11/2022 | View on chart |
| PRCT | ▼ Sell | Other | 56,159 | — | 9/17/2021 | View on chart |
| PRCT | ▲ Buy | Open Market | 6,800 | $170K | 9/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
THINK Surgical Names Rick McDowell VP of Sales
THINK Surgical, a subsidiary of PROCEPT BioRobotics, has appointed Rick McDowell as Vice President of Sales. This leadership addition is intended to support the company's commercial operations. The stock is currently trading near its 52-week low, with an average analyst target of $21.64.
THINK Surgical Names Rick McDowell VP of Sales. THINK Surgical, a subsidiary of PROCEPT BioRobotics, has appointed Rick McDowell as Vice President of Sales. This leadership addition is intended to support the company's commercial operations. The stock is currently trading near its 52-week low, with an average analyst target of $21.64.